Biotech company Q BioMed has signed an exclusive distribution agreement for its Strontium89 (strontium-89 chloride injection) therapeutic radiopharmaceutical with Canadian distributor isoSolutions Marketing & Management.
Under the deal, isoSolutions will distribute Q BioMed's Strontium89 radiopharmaceutical in Canada for the treatment of painful skeletal metastases. It's available now under Canada's Named Patient Program, according to Q BioMed.
The vendor said it's also actively pursuing full regulatory and marketing approval for Strontium89 in Canada and other markets worldwide.
